Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Diana Basali
Real-World Data on Safety and Efficacy of Venetoclax-Based Regimens in Relapsed/Refractory T(11;14) Multiple Myeloma
British Journal of Haematology
Hematology
Related publications
Successful Venetoclax Salvage in the Setting of Refractory, Dialysis-Dependent Multiple Myeloma With T(11;14)
Haematologica
Hematology
Efficacy and Safety of Long-Term Treatment With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Blood Cancer Journal
Oncology
Hematology
Carfilzomib for Relapsed or Refractory Multiple Myeloma
The Lancet Oncology
Oncology
Bendamustine in Patients With Relapsed or Refractory Multiple Myeloma
European Journal of Medical Research
Medicine
Systematic Review and Meta-Analysis of the Efficacy and Safety of Novel Monoclonal Antibodies for Treatment of Relapsed/Refractory Multiple Myeloma
Oncotarget
Oncology
Daratumumab, Bortezomib and Dexamethasone (Dvd) vs Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Efficacy and Safety Update (Castor)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Daratumumab, Lenalidomide, and Dexamethasone (Drd) vs Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Efficacy and Safety Update (Pollux)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
MYEOV (Myeloma Overexpressed (In a Subset of T(11;14) Positive Multiple Myelomas))
Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer Research
Oncology
Genetics
Hematology
PHASE 1B STUDY OF ViPOR (VENETOCLAX, IBRUTINIB, PREDNISONE, OBINUTUZUMAB, LENALIDOMIDE) IN RELAPSED/REFRACTORY B-Cell LYMPHOMA: SAFETY, EFFICACY AND MOLECULAR ANALYSIS
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
